1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2017 // www.goldcopd.com.
2. Eisner M.D., Anthonisen N., Coultas D. et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182: 693-718.
3. Lamprecht B, McBurnie MA, Vollmer WM, et al., BOLD Collaborative Research Group: COPD in never smokers: results form the population-based burden of obstructive lung disease study. Chest 2011;139: 752-763.
4. Mehta AJ, Miedinger D, Keidel D. et al., The SAPALDIA Team. Occupational exposure to dusts, gases, and fumes and incidence of chronic obstructive pulmonary disease in the Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults. Am J Respir Crit Care Med 2012; 185:1292-1300.
5. Silva GE, Sherrill DL, Guerra S et al. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004; 126: 59-65.
6. Brutsche MH, Downs SH, Schindler C, Gerbase MW, Schwartz J, Frey M, Russi EW, Ackermann-Liebrich U, Leuenberger P: Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax 2006; 61: 671-677.
7. de Marco R, Accordini S, Marcon A, Cerveri I, Anto JM, Gislason T, Heinrich J, Janson C, Jarvis D, Kuenzli N, Leynaert B, Sunyer J, Svanes C, Wjst M, Burney P, European Community Respiratory Health Survey (ECRHS): Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am J Respir Crit Care Med 2011; 183: 891-897.
8. de Marco R, Accordini S, Cerveri I, Corsico A, Anto JM, Kunzli N, Janson C, Sunyer J, Jarvis D, Chinn S, Vermeire P, Svanes C, Ackermann-Liebrich U, Gislason T, Heinrich J, Leynaert B, Neukirch F, Schouten JP, Wjst M, Burney P: Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 2007; 175: 32-39.
9. Bridevaux PO, Gerbase MW, Probst-Hensch NM, Schindler C, Gaspoz JM, Rochat T: Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax 2008; 63: 768- 774.
10. Stoller JK: Clinical features and natural history of severe alpha-1-antitrypsin deficiency. Chest 1997;111:123S-128S.
11. Stoller JK, Aboussouan LS: A review of alpha- 1-antitrypsin deficiency. Am J Respir Crit Care Med 2012;185: 246-259.
12. Smolonska J, Wijmenga C, Postma DS, Boezen HM: Meta-analyses on suspected chronic obstructive pulmonary disease genes: a summary of 20 years’ research. Am J Respir Crit Care Med 2009;180: 618-631.
13. Chuchalin AG, Khaltaev N, Antonov NS et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation // Int J COPD 2014; 12: 963-74.
14. World Health Organization.Evidence-informed policy-making.2016. http ://www.who.int/evidence
15. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2011 // www.goldcopd.com.
16. Celli B, MacNee W, ATS/ERS Task Force: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ ERS position paper. Eur Respir J 2004; 23: 932-946.
17. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA: Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-586.
18. Jones PW, Harding G, Berry P. Wiklund I, Chen WH, Kline Leidy N: Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34: 648-654.
19. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
20. Barnes PJ, Celli BR: Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-1185.
21. Hill K, Goldstein RS, Guyatt GH et al. Prevalence and underdiagnosis of chronic obstructive pulmonary diseaseamong patients at risk im primary care // CMAJ 2010; 182(7): 673-8.
22. Pellegrino R, Viegi G, Brusasco V. et al. Interpretative strategies for lung functiom tasts // Eur Respir J 2005; 26: 948-68.
23. Miller MR, Hankinson J, Brusasco V. et al. Standardisation of spirometry // Eur Respir J 2005; 26(2): 319-38.
24. Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C et al. Bronchodilator responsiveness in patients with COPD // Eur Respir J 2008;31:742-50.
25. Quanjer PH, Tammeling GJ, Cotes JE et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European 80 Community for Steel and Coal. Official Statement of the European Respiratory Society // Eur Respir J. 1993, 6: suppl. 16, 540.
26. Wanger J, Clausen JL, Coates A et al. Standardisation of the measurement of lung volumes // Eur Respir J 2005; 26: 511-522.
27. Amalakanti S, Pentakota MR Pulse Oximetry Overestimates Oxygen Saturtion in COPD // Respir Care 2016; 61 (4): 423-7.
28. Casanova C, Cote CG, Marin JM et al. Test 6-min walking distance: long-term follow up in patients with COPD // Eur Respir J 2007; 29(3): 535-40.
29. Oga T, Nishimura K, Tsukino M. et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status // Am J Respir Crit Care Med 2003; 167(4): 544-9.
30. Fishman A, Martinez F, Naunheim K et al. A randomized trial comparinglung-volume-reduction surgery with medical therapy for severe emphysema // N Engl J Med 2003; 348 (21): 2059-73
31. Kelly AM, McAlpine R, Kyle E How accurate are pulse oximeters in patientswith acute exacerbationsof chronic obstructive airways disease? Respir Med 2001; 95 (5): 336-40.